JP2018534316A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534316A5
JP2018534316A5 JP2018525743A JP2018525743A JP2018534316A5 JP 2018534316 A5 JP2018534316 A5 JP 2018534316A5 JP 2018525743 A JP2018525743 A JP 2018525743A JP 2018525743 A JP2018525743 A JP 2018525743A JP 2018534316 A5 JP2018534316 A5 JP 2018534316A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
substituted
tumors
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018525743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534316A (ja
JP6946290B2 (ja
Filing date
Publication date
Priority claimed from GBGB1520499.3A external-priority patent/GB201520499D0/en
Application filed filed Critical
Publication of JP2018534316A publication Critical patent/JP2018534316A/ja
Publication of JP2018534316A5 publication Critical patent/JP2018534316A5/ja
Application granted granted Critical
Publication of JP6946290B2 publication Critical patent/JP6946290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018525743A 2015-11-20 2016-11-16 Mnk阻害剤としてのピロロピリミジン化合物 Expired - Fee Related JP6946290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520499.3 2015-11-20
GBGB1520499.3A GB201520499D0 (en) 2015-11-20 2015-11-20 Compounds
PCT/GB2016/053579 WO2017085483A1 (en) 2015-11-20 2016-11-16 Pyrropyrimidine compounds as mnks inhibitors

Publications (3)

Publication Number Publication Date
JP2018534316A JP2018534316A (ja) 2018-11-22
JP2018534316A5 true JP2018534316A5 (enExample) 2019-12-26
JP6946290B2 JP6946290B2 (ja) 2021-10-06

Family

ID=55133105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525743A Expired - Fee Related JP6946290B2 (ja) 2015-11-20 2016-11-16 Mnk阻害剤としてのピロロピリミジン化合物

Country Status (9)

Country Link
US (1) US10604524B2 (enExample)
EP (2) EP3792264B1 (enExample)
JP (1) JP6946290B2 (enExample)
CN (1) CN108368114B (enExample)
AU (1) AU2016355103B2 (enExample)
CA (1) CA3003554C (enExample)
ES (2) ES2972862T3 (enExample)
GB (1) GB201520499D0 (enExample)
WO (1) WO2017085483A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
WO2018152117A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
CN1237177A (zh) * 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
BR9916746A (pt) 1999-06-03 2005-01-11 Abbott Lab Compostos anti-inflamatórios que inibem adesão de célula
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド c−Metモジュレーター及び使用方法
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
CN101466716A (zh) * 2006-04-07 2009-06-24 德维洛根股份公司 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP5626748B2 (ja) * 2008-07-02 2014-11-19 キッコーマン株式会社 ペプチド含有調味料
BR112012021453A2 (pt) 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
PH12012501693A1 (en) * 2010-02-26 2012-11-05 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
JP2016506944A (ja) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Similar Documents

Publication Publication Date Title
JP2016530283A5 (enExample)
JP2018534316A5 (enExample)
CN107108637B (zh) 三唑并嘧啶化合物及其用途
JP2018534314A5 (enExample)
JP2014503567A5 (enExample)
JP2016519653A5 (enExample)
JP2017071634A5 (enExample)
MX387207B (es) Inhibidores de proteína quinasa, método de preparación y su uso médico.
CN109906224B (zh) 三唑吡啶化合物及其应用
JP2019524883A5 (enExample)
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
JP2016053042A5 (enExample)
JP2016523974A5 (enExample)
JP2018533611A5 (enExample)
RU2018104702A (ru) Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
JP2014518544A5 (enExample)
JP2019510810A5 (enExample)
JP2018522866A5 (enExample)
JP2013056930A5 (enExample)
JP2017509586A5 (enExample)
JP2016501223A5 (enExample)
RU2016134751A (ru) Соединения
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
RU2015143841A (ru) Ингибиторы hdac
RU2016110096A (ru) Новое хинолин-замещенное соединение